Bafna Pharmaceuticals quarterly results and financials

Bafna Pharmaceuticals (BAFNAPH)₹472.80+2.00%(9 Nov 2026 close)Pharmaceuticals

Key facts

In the Mar 2026 quarter (standalone), Bafna Pharmaceuticals reported sales of ₹42.08 Cr, up 8.1% from Mar 2025, and net profit of ₹2.76 Cr, up 109.1% year on year. For the year to Mar 2026, sales were ₹150 Cr and net profit ₹11.04 Cr.

Sales (Mar 2026): ₹42.08 Cr
Net profit (Mar 2026): ₹2.76 Cr
Sales (FY Mar 2026): ₹150 Cr
Net profit (FY Mar 2026): ₹11.04 Cr
EPS (Mar 2026): ₹1.17
Borrowings (Mar 2026): ₹36.96 Cr

Company filings, standalone accounts; latest reported quarter Mar 2026

Bafna Pharmaceuticals quarterly results

₹ crore unless stated; each column is a quarter.

Bafna Pharmaceuticals Quarterly results
	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	41.79	40.55	28.37	41.23	33.19	40.21	33.07	38.94	34.49	35.34	38.16	42.08
Expenses	35.62	36.62	30.45	38.44	32.04	36.51	30.08	35.89	29.52	31.13	35.22	38.63
Operating Profit	6.28	4.00	−2.06	2.88	1.20	3.78	3.05	3.10	5.06	4.27	3.04	3.54
OPM %	15.0%	9.9%	−7.3%	7.0%	3.6%	9.4%	9.2%	8.0%	14.6%	12.1%	8.0%	8.4%
Other Income	1.86	0.15	0.97	0.51	0.15	1.01	0.17	−0.75	0.59	1.17	1.21	1.75
Interest	0.59	0.43	0.59	0.67	0.66	0.63	0.65	0.83	0.92	0.87	0.87	1.04
Depreciation	1.22	1.25	1.28	1.28	1.45	1.59	1.67	0.23	1.38	1.48	1.58	1.67
Profit before tax	6.34	2.48	−2.93	1.45	−0.71	2.60	0.93	1.30	3.38	3.12	1.83	2.61
Tax %	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	−4.9%
Exceptional items	0.00	0.00	0.00	0.00	−0.36	0.00	−0.02	−1.80	0.00	0.00	0.00	0.00
Net Profit	6.37	2.49	−2.95	1.47	−0.73	2.63	0.96	1.32	3.40	3.13	1.85	2.76
EPS (Rs)	2.69	1.06	−1.25	0.63	−0.31	1.12	0.41	0.56	1.44	1.33	0.79	1.17

Bafna Pharmaceuticals profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Bafna Pharmaceuticals Profit and loss
	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	84.72	64.73	45.85	43.84	41.85	70.79	84.71	115	151	146	150	150
Expenses	81.86	69.88	80.97	56.98	40.96	60.91	72.93	99.83	141	135	135	135
Operating Profit	2.99	−4.99	−34.90	−12.97	0.99	9.97	11.97	15.97	10.97	10.97	15.95	15.91
OPM %	3.3%	−8.0%	−77.0%	−30.0%	2.9%	14.0%	14.0%	14.0%	7.0%	8.0%	11.0%	10.6%
Other Income	0.99	0.99	30.90	0.00	−22.92	0.99	0.00	2.99	3.99	0.99	4.98	4.72
Interest	12.01	10.99	6.99	2.01	0.00	1.01	1.01	2.01	1.99	3.01	4.01	3.70
Depreciation	4.01	4.01	4.01	3.01	3.01	4.01	5.01	5.01	5.01	5.01	6.01	6.11
Profit before tax	−12.97	−18.97	−13.98	−17.97	−24.94	5.99	4.99	11.97	6.98	3.99	10.97	10.94
Tax %	−3.0%	−4.0%	15.0%	8.1%	0.0%	0.0%	0.0%	2.0%	0.0%	0.0%	−1.0%	—
Exceptional items	0.00	0.00	28.07	0.00	−23.05	0.00	−2.01	0.00	0.00	−2.01	0.00	0.00
Net Profit	−12.04	−18.06	−16.04	−20.08	−25.08	6.02	5.01	11.04	7.03	4.01	11.04	11.14
EPS (Rs)	−6.55	−9.93	−6.97	−8.35	−106.73	2.47	2.22	4.80	3.12	1.76	4.70	4.73
Dividend payout %	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—

Bafna Pharmaceuticals balance sheet

₹ crore, at each year end.

Bafna Pharmaceuticals Balance sheet
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	19.01	18.99	18.99	23.99	24.04	2.00	23.98	23.98	23.99	24.00	23.97	24.01
Reserves	53.04	41.01	26.02	17.00	−3.01	49.03	32.99	38.00	50.03	57.05	60.99	72.02
Borrowings	63.94	79.85	81.90	46.89	45.98	3.00	14.97	10.98	22.96	23.96	27.94	36.96
Other Liabilities	49.76	44.79	39.81	39.81	53.74	16.92	13.94	16.92	32.84	41.81	39.81	41.79
Total Liabilities	185	185	167	128	121	70.95	85.88	89.88	130	148	153	176
Fixed Assets	49.08	47.06	43.08	40.05	37.07	35.08	36.07	39.08	40.10	40.10	59.07	82.15
CWIP	0.00	0.00	0.00	0.00	0.00	0.00	0.99	0.00	1.99	11.96	6.98	2.99
Investments	17.99	17.98	17.97	0.99	0.99	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	118	120	106	85.65	81.69	35.87	49.82	50.80	87.73	94.76	86.66	90.64
Inventories	15.30	16.31	16.71	10.64	9.26	11.39	15.40	20.23	22.18	29.56	28.01	28.85
Trade receivables	83.12	67.68	53.50	24.18	24.73	6.01	9.53	14.73	40.99	45.24	40.04	43.78
Cash & equivalents	2.46	2.71	2.67	2.71	2.71	8.49	1.81	0.18	7.82	1.41	3.44	2.03
Total Assets	185	185	167	128	121	70.95	85.88	89.88	130	148	153	176

Bafna Pharmaceuticals cash flow

₹ crore, for each year.

Bafna Pharmaceuticals Cash flow
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	9.03	−3.01	14.04	−7.02	−1.01	−34.10	−14.05	10.03	5.02	9.03	22.08	15.05
Cash from investing activity	55.99	−0.99	−7.99	37.98	4.01	32.97	−4.99	−6.99	−6.99	−14.99	−20.98	−21.98
Cash from financing activity	−66.06	4.01	−5.01	−31.03	−1.99	7.01	11.99	−4.99	10.01	−1.01	1.01	6.01
Net cash flow	0.00	0.00	0.00	0.00	0.00	5.99	−6.99	−1.99	7.99	−5.99	1.99	−0.99
Capex	7.70	2.28	0.07	0.12	0.32	1.42	6.07	7.51	6.70	15.55	21.81	24.81
Free cash flow	2.01	−5.02	20.06	40.15	−1.01	−36.10	−20.06	2.01	−2.01	−6.02	0.00	−10.03
CFO / OP %	−74.0%	−106.1%	−263.1%	19.9%	8.0%	−2,786.1%	−132.1%	82.9%	31.9%	86.9%	194.0%	95.9%

Bafna Pharmaceuticals ratios

Working-capital days and returns, by year.

Bafna Pharmaceuticals Ratios
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	303	291	302	195	208	52	49	63	130	109	101	106
Inventory days	65	91	117	101	121	207	153	184	128	124	126	128
Days payable	150	170	165	266	518	230	108	114	166	150	141	140
Cash conversion cycle	220	214	255	31	−188	31	96	135	94	84	88	96
Working capital days	56	125	−36	−108	−210	89	121	123	104	92	74	74
ROCE %	−13.1%	0.0%	−6.0%	−35.0%	−21.1%	−3.0%	10.0%	11.0%	15.9%	9.0%	7.9%	11.9%

Bafna Pharmaceuticals: frequently asked questions

What are the latest quarterly results of Bafna Pharmaceuticals?

For the Mar 2026 quarter, Bafna Pharmaceuticals reported sales of ₹42.08 Cr, up 8.1% year on year and net profit of ₹2.76 Cr, up 109.1% year on year. The operating margin was 8.4%.

What is the annual revenue of Bafna Pharmaceuticals?

Bafna Pharmaceuticals' sales for the year to Mar 2026 were ₹150 Cr; over the last twelve months they were ₹150 Cr.

What is the net profit of Bafna Pharmaceuticals?

Net profit for the year to Mar 2026 was ₹11.04 Cr, and ₹11.14 Cr over the last twelve months. Earnings per share over the same trailing period were ₹4.73.

How much debt does Bafna Pharmaceuticals have?

Bafna Pharmaceuticals reported borrowings of ₹36.96 Cr at Mar 2026, against cash and equivalents of ₹2.03 Cr.

What is the free cash flow of Bafna Pharmaceuticals?

Cash from operations was ₹15.05 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹10.03 Cr.

Loading…